News | Radial Access | June 15, 2017

No Difference in Adverse Events When Comparing Anticoagulants

NCDR report compares outcomes using bivalirudin, heparin in STEMI patients

radial access, transradial access trial using anticoagulants

June 15, 2017 — In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study published in May in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.

Using data from the National Cardiovascular Data Registry CathPCI Registry, researchers examined the records of 67,368 patients from 1,584 sites between 2009 to 2015 with STEMI who underwent primary PCI via radial access. Of these patients, 29,660 received bivalirudin and 37,708 received heparin. The groups did not differ substantially in mean age (60.3 and 60.4, respectively) or percentage of men (74.9 and 75 percent, respectively).

The researchers adjusted for multiple variables, including a propensity score reflecting the probability of receiving bivalirudin to account for patient differences between groups. After these adjustments, the odds ratio of the composite endpoint of death, myocardial infarction or stroke for bivalirudin versus heparin was not statistically significant (0.95); the odds ratio for acute stent thrombosis was 2.11 for bivalirudin versus heparin. Major bleeding rates were not significantly different.

Ion S. Jovin, M.D., FACC, the study’s lead author and medical director of the cardiac catheterization laboratories at McGuire Veterans Affairs Medical Center and associate professor of medicine at Virginia Commonwealth University, said that the study’s results are consistent with data from contemporary studies of patients with acute coronary syndrome and STEMI.

“Our sensitivity analysis provides some insights into direct comparisons of bivalirudin and heparin when GPIIb/IIIa inhibitors are forced out of the equation and suggests that in the direct comparison bivalirudin may have superior outcomes,” Jovin said. “However, our study showed that in the real world over a third of the patients with STEMI undergoing transradial PCI who receive heparin and about a fifth of patients who receive bivalirudin also receive GPIIb/IIIa inhibitors.”

The authors suggested that a randomized trial in patients treated exclusively via transradial primary PCI and anticoagulated with bivalirudin versus heparin as well as a cost-effectiveness analysis comparing heparin versus bivalirudin would help practitioners and hospitals make better decisions regarding anticoagulation in these patients.

For more information: JACC.org

Related Content

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

The U.S. Food and Drug Administration (FDA) has approved two applications for the first generics of the anticoagulant Eliquis (apixaban).

Feature | Antiplatelet and Anticoagulation Therapies | December 27, 2019
December 27, 2019 — The U.S.
aspirin bottle
News | Antiplatelet and Anticoagulation Therapies | December 12, 2019
December 12, 2019 — Low-dose aspirin was not associated with a reduced risk of a fatal heart attack among African Ame
Videos | Antiplatelet and Anticoagulation Therapies | October 11, 2019
Ajay J. Kirtane, M.D., associate professor of medicine at Columbia University Irving Medical Center and director of the...
Videos | Antiplatelet and Anticoagulation Therapies | October 08, 2019
American Heart Association President Robert Harrington, M.D., explains the reasons for shorter duration dual-...
Three-Month DAPT Post-PCI Demonstrates Low Adverse Event Rate in High-Bleeding Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 30, 2019
Data from the EVOLVE Short DAPT study found that shortened three-month dual antiplatelet therapy (DAPT) did not...
Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients
News | Antiplatelet and Anticoagulation Therapies | September 26, 2019
New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy reduced the risk of BARC...
Aspirin Should Not Be Recommended for Healthy People Over 70
News | Antiplatelet and Anticoagulation Therapies | September 20, 2019
Low-dose aspirin does not prolong disability-free survival of healthy people over 70, even in those at the highest risk...
Ticagrelor Plus Aspirin Reduces Ischemic Events in Stable Coronary Patients With Diabetes
News | Antiplatelet and Anticoagulation Therapies | September 10, 2019
The combination of ticagrelor and aspirin reduces ischemic events compared with aspirin alone in patients with stable...
Overlay Init